Analysts Set IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Price Target at $53.67

IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Get Free Report) has received an average rating of "Moderate Buy" from the sixteen research firms that are currently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $53.67.

A number of research firms have issued reports on IDYA. Leerink Partners downgraded IDEAYA Biosciences from an "outperform" rating to a "market perform" rating and decreased their target price for the stock from $41.00 to $27.00 in a research report on Tuesday, November 5th. Cantor Fitzgerald reiterated an "overweight" rating on shares of IDEAYA Biosciences in a research note on Tuesday, December 17th. Stephens assumed coverage on shares of IDEAYA Biosciences in a research note on Monday, November 18th. They set an "overweight" rating and a $51.00 price target on the stock. Royal Bank of Canada reiterated an "outperform" rating and issued a $61.00 price objective on shares of IDEAYA Biosciences in a research note on Tuesday, September 24th. Finally, Wedbush restated an "outperform" rating and set a $52.00 target price on shares of IDEAYA Biosciences in a research report on Tuesday, December 17th.

Institutional Investors Weigh In On IDEAYA Biosciences

Institutional investors and hedge funds have recently bought and sold shares of the stock. Allworth Financial LP increased its position in shares of IDEAYA Biosciences by 800.0% during the 3rd quarter. Allworth Financial LP now owns 900 shares of the company's stock valued at $29,000 after purchasing an additional 800 shares during the last quarter. Covestor Ltd raised its position in IDEAYA Biosciences by 23,050.0% during the 3rd quarter. Covestor Ltd now owns 926 shares of the company's stock valued at $29,000 after purchasing an additional 922 shares during the last quarter. Quest Partners LLC purchased a new stake in IDEAYA Biosciences in the second quarter worth $41,000. US Bancorp DE increased its position in shares of IDEAYA Biosciences by 67.2% during the third quarter. US Bancorp DE now owns 1,714 shares of the company's stock valued at $54,000 after buying an additional 689 shares during the period. Finally, Daiwa Securities Group Inc. raised its position in shares of IDEAYA Biosciences by 637.9% in the 2nd quarter. Daiwa Securities Group Inc. now owns 1,948 shares of the company's stock worth $68,000 after acquiring an additional 1,684 shares in the last quarter. 98.29% of the stock is owned by hedge funds and other institutional investors.

IDEAYA Biosciences Stock Performance

Shares of IDEAYA Biosciences stock traded down $0.82 on Friday, hitting $24.03. The company had a trading volume of 647,977 shares, compared to its average volume of 867,354. The stock has a market capitalization of $2.08 billion, a price-to-earnings ratio of -10.31 and a beta of 0.82. The stock has a 50 day moving average of $26.89 and a 200-day moving average of $32.68. IDEAYA Biosciences has a 1 year low of $23.98 and a 1 year high of $47.74.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last announced its quarterly earnings data on Monday, November 4th. The company reported ($0.60) EPS for the quarter, topping the consensus estimate of ($0.63) by $0.03. During the same quarter in the prior year, the business posted ($0.46) earnings per share. Equities analysts anticipate that IDEAYA Biosciences will post -2.45 earnings per share for the current year.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.